Overview

• AstraZeneca will invest $50 billion in U.S. manufacturing and research by 2030.
• The new Virginia facility will be the company’s largest global investment in drug production to date.
• Earlier this year, AstraZeneca began shifting European output to the U.S. after President Trump threatened tariffs of up to 200 percent on medicines.
• Commerce Secretary Howard Lutnick praised the investment as essential for addressing structural weaknesses in American pharmaceutical supply chains.
• Peer companies including Sanofi, Novartis and Eli Lilly have also pledged tens of billions of dollars for U.S. production relocations to mitigate trade‐policy risks.